New and emerging technologies for the treatment of inherited retinal diseases: A horizon scanning review

Eye (Basingstoke)

Volumn 29, Issue 9, 2015, Pages 1131-1140

  Smith, J ^a   Ward, D ^a   Michaelides, M ^b,c   Moore, A T ^b,c   Simpson, S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ALK 001; BRIMONIDINE; EMIXUSTAT; FENRETINIDE; QLT 091001; RETINAL; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER; VALPROIC ACID;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CELL THERAPY; CHOROIDEREMIA; CLINICAL EFFECTIVENESS; DISEASE CONTROL; DRUG EFFICACY; EMBRYONIC STEM CELL; GENE REPLACEMENT THERAPY; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GLIA CELL; HUMAN; INHERITED RETINAL DISEASE; LEBER CONGENITAL AMAUROSIS; MEDICAL DEVICE; MEDICAL TECHNOLOGY; NONHUMAN; OPHTHALMOLOGICAL EQUIPMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR CELL; PIGMENT CELL; REGENERATIVE MEDICINE; RETINA DISEASE; RETINAL IMPLANT; RETINITIS PIGMENTOSA; STARGARDT DISEASE; STEM CELL; STEM CELL TRANSPLANTATION; USHER SYNDROME; VIRAL GENE DELIVERY SYSTEM; BLINDNESS; CLINICAL TRIAL (TOPIC); PROCEDURES; PROSTHESES AND ORTHOSES; RETINAL DISEASES;

BIOMEDICAL TECHNOLOGY; BLINDNESS; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; HUMANS; PROSTHESES AND IMPLANTS; REGENERATIVE MEDICINE; RETINAL DISEASES;

EID: 84941214500     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.115     Document Type: Article

References (20)

1. Sundaram V, Moore AT, Ali RR, Bainbridge JW. Retinal dystrophies and gene therapy. Eur J Pediatr 2012; 171(5): 757-765.
2. RP Fighting Blindness. Other Inherited Retinal Conditions. http://www.rpfightingblindness.org.uk/index.php?tln= aboutrp&pageid=66.
3. Moore T, Burton H. Genetic Ophthalmology in Focus: A Needs Assessment and Review of Specialist Services for Genetic Eye Disorders PHG Foundation 2008. Available at http://www.phgfoundation.org/pages/work2.htm.
4. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014; 4: e004015.
5. Rahi JS, Cable N. British Childhood Visual Impairment Study Group. Severe visual impairment and blindness in children in the UK. Lancet 2003; 362: 1359-1365.
6. Patient: trusted medical information and support. Hereditary retinal dystrophies. Available at http://www. patient.co.uk/doctor/Hereditary-Retinal-Dystrophies.htm.
7. Rowe F, Wormald R, Cable R, Acton M, Bonstein K, Bowen M, et al. The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research prioritisation survey process. BMJ Open 2014; 4(7): e004905.
8. EuroScan International Network. EuroScan International Network. A toolkit for the identification and assessment of new and emerging technologies, 2014. Birmingham: Euroscan International Network. Available at http:// euroscan.org.uk/methods.
9. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4(120): 120ra15.
10. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012; 130(1): 9-24.
11. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358(21): 2231-2239.
12. McClements M, Maclaren RE. Gene therapy for retinal disease. Transl Res 2013; 161(4): 241-254.
13. McGrath D. Inherited Retinal Disease: Current Research is Focusing on Optimising the AV Delivery Vector to Enhance Gene Expression. Available at www.nets.nihr.ac.uk/ identifying-research/james-lind-Alliance.
14. Borooah S, Phillips MJ, Bilican B, Wright AF, Wilmut I, Chandran S, et al. Using human induced pluripotent stem cells to treat retinal disease. Prog Retin Eye Res 2013; 37: 163-181.
15. Huang Y, Enzmann V, Ildstad ST. Stem cell-based therapeutic applications in retinal degenerative diseases. Stem Cell Rev 2011; 7(2): 434-445.
16. Zheng A, Li Y, Tsang SH. Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin Biol Ther 2015; 15: 391-402.
17. The Wellcome Trust. The Wellcome Trust. The ethics of stem cells. Available at http://www.wellcome.ac.uk/About-us/ Policy/Spotlight-issues/Human-Fertilisation-And-Embryology-Act/Stem-cell-basics/WTD040077.htm.
18. Neurotech. NT-501 CNTF Renexus. Available at http://www.neurotechusa.com/cntfrenexus.html. Accessed January 2015.
19. Zein WM, Jeffrey BG, Wiley HE, Turriff AE, Tumminia SJ, Tao W, et al. CNGB3-Achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci 2014; 55(10): 6301-6308.
20. Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W. Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Group. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013; 156(2): 283-292.e1.